Providers utilize business intelligence to monitor referral patterns and collaborate with clinicians who order their services. Such analytics tools have also been deployed in the specialty to improve productivity, track patient satisfaction and bolster quality.
Make way for MiniMed! Medtronic's diabetes division has filed the necessary paperwork to go public. The company hopes to be traded on Nasdaq under the symbol MMED.
The Pennsylvania-based drug distributor announced it would be buying OneOncology, a physician-led specialty service group in which it already owned a minority stake. The company said the acquisition will complement its "pharmaceutical-centric strategy."
Paxton says the “woke” EHR giant is intentionally making it harder for patients and families to access historical medical data, violating state law. Epic denies the allegation.
Mark Cuban's startup Cost Plus Drugs and insurer Humana are said to be working on a deal that would allow Medicare Advantage patients to buy drugs directly from manufacturers. The terms of the agreement—which Forbes reports is in its early stages—are still unknown.
The U.S. Department of Justice said policies at CVS Health forbade pharmacists from discussing patients and providers who may be prescribing opiates in violation of the Controlled Substance Act.
The Center for Vein Restoration has notified patients about a data breach that occurred in October, exposing financial and medical information on patients from across the U.S.
When regulating AI-equipped medical devices, the FDA might take a page from the Department of Transportation’s playbook for overseeing AI-equipped vehicles. These run the gamut from assisting human drivers to fully taking the wheel.
Last Christmas, Anna Jaques Hospital in Massachusetts suffered a ransomware attack. Now, nearly a year later, it confirms hackers stole personal information on 316,342 patients.
The Federal Trade Commission did not accuse the companies of wrongdoing. However, it advised them to stay out of trouble by not deploying robocalls, impersonating the government or other common illegal marketing strategies.